Therefore, 1,25(OH)2D3 treatment combined with silencing hCAP18/LL-37 expression may be a potential strategy to increase the anticancer activity of 1,25(OH)2D3 in treating HCC progression. This evidence concerns the gene CAMP and hepatocellular carcinoma.